Previous Close | 13.46 |
Open | 13.55 |
Bid | 13.03 x 800 |
Ask | 13.36 x 1100 |
Day's Range | 12.52 - 13.55 |
52 Week Range | 9.39 - 35.73 |
Volume | |
Avg. Volume | 84,016 |
Market Cap | 547.503M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.56 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 31.33 |
SAN DIEGO, August 09, 2022--Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Janux Therapeutics, Inc. ( NASDAQ:JANX ) shareholders should be happy to see the share price up 13% in the last month...
SAN DIEGO, June 02, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 11:00 a.m. ET in New York, New York.